Concepts (75)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antibodies, Monoclonal, Humanized | 2 | 2019 | 151 | 0.750 |
Why?
|
| Quinolines | 1 | 2020 | 48 | 0.720 |
Why?
|
| Anilides | 1 | 2019 | 16 | 0.690 |
Why?
|
| Arthralgia | 1 | 2019 | 30 | 0.650 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2019 | 110 | 0.640 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 468 | 0.640 |
Why?
|
| B7-H1 Antigen | 1 | 2018 | 30 | 0.630 |
Why?
|
| Kidney Neoplasms | 1 | 2019 | 206 | 0.620 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 87 | 0.610 |
Why?
|
| Neoplasms | 5 | 2019 | 1667 | 0.600 |
Why?
|
| Pyridines | 1 | 2019 | 261 | 0.590 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 186 | 0.580 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 331 | 0.560 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 511 | 0.520 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 1070 | 0.470 |
Why?
|
| Protein-Lysine 6-Oxidase | 1 | 2006 | 14 | 0.280 |
Why?
|
| Cell Hypoxia | 1 | 2006 | 92 | 0.270 |
Why?
|
| Neoplasm Metastasis | 1 | 2006 | 306 | 0.250 |
Why?
|
| Retrospective Studies | 3 | 2019 | 7277 | 0.210 |
Why?
|
| Aged | 5 | 2019 | 14862 | 0.190 |
Why?
|
| Cyclopropanes | 1 | 2020 | 10 | 0.190 |
Why?
|
| Cetuximab | 1 | 2020 | 19 | 0.190 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2021 | 33 | 0.180 |
Why?
|
| Premedication | 1 | 2020 | 49 | 0.180 |
Why?
|
| Sulfides | 1 | 2020 | 43 | 0.180 |
Why?
|
| Acetates | 1 | 2020 | 74 | 0.180 |
Why?
|
| Ipilimumab | 1 | 2019 | 10 | 0.170 |
Why?
|
| Middle Aged | 5 | 2019 | 21147 | 0.160 |
Why?
|
| Arthritis | 1 | 2018 | 53 | 0.160 |
Why?
|
| Nausea | 1 | 2018 | 47 | 0.150 |
Why?
|
| Medication Therapy Management | 1 | 2018 | 32 | 0.150 |
Why?
|
| Vomiting | 1 | 2018 | 56 | 0.150 |
Why?
|
| Pharmaceutical Services | 1 | 2018 | 47 | 0.150 |
Why?
|
| Pneumonia | 1 | 2018 | 110 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 66 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 536 | 0.140 |
Why?
|
| Humans | 10 | 2021 | 68618 | 0.140 |
Why?
|
| Male | 6 | 2021 | 37321 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 848 | 0.130 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 300 | 0.120 |
Why?
|
| Female | 5 | 2019 | 38074 | 0.120 |
Why?
|
| Proteins | 1 | 2018 | 474 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 1173 | 0.080 |
Why?
|
| Retinoblastoma Protein | 1 | 2008 | 75 | 0.080 |
Why?
|
| Protein Kinases | 1 | 2008 | 122 | 0.080 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2007 | 5 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2008 | 110 | 0.080 |
Why?
|
| Tamoxifen | 1 | 2007 | 62 | 0.070 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2007 | 99 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 446 | 0.040 |
Why?
|
| Intersectoral Collaboration | 1 | 2018 | 27 | 0.040 |
Why?
|
| Outpatients | 1 | 2018 | 127 | 0.040 |
Why?
|
| Pharmacists | 1 | 2018 | 125 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2018 | 376 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 800 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 1342 | 0.030 |
Why?
|
| Animals | 2 | 2007 | 20881 | 0.030 |
Why?
|
| Time Factors | 1 | 2018 | 4655 | 0.020 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2008 | 17 | 0.020 |
Why?
|
| Leupeptins | 1 | 2008 | 23 | 0.020 |
Why?
|
| Proteasome Inhibitors | 1 | 2008 | 29 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2008 | 90 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 2008 | 130 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2008 | 118 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2008 | 215 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2007 | 301 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 7029 | 0.020 |
Why?
|
| United States | 1 | 2018 | 7367 | 0.020 |
Why?
|
| Cell Survival | 1 | 2008 | 901 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2008 | 1200 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 659 | 0.020 |
Why?
|
| Phenotype | 1 | 2007 | 947 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 981 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2008 | 1851 | 0.010 |
Why?
|
| Adult | 1 | 2018 | 21403 | 0.010 |
Why?
|